Managers

New Israeli VC Grove Ventures is betting big on hardware

Renault-Nissan sets up $200 million fund to tap startups: Reuters

The Renault-Nissan-Mitsubishi alliance is pooling $200 million in a new mobility tech fund, three sources said, in the latest move by major carmakers to adapt to rapid industry change by investing in startups through their own venture capital arms.

Healthcare venture fundraising and investments reached record-highs in 2017

BlueIO Management to raise venture capital fund

BlueIO Management has set out to raise a venture capital fund named Series Virsec, according to a filing with the SEC.

North American cannabis venture investments grew in H2 2017

Gene therapy company Immusoft takes in $3 mln

Seattle-based gene therapy company Immusoft has closed the first part of its Series B funding round at $3 million. The lead investor was 600 Mile Challenge Fund. In addition to this transaction, Sean Ainsworth, who founded and led RetroSense Therapeutics, is Immusoft's new CEO and board chairman. Also, Dr. Anthony Sun has been added to the board.

Fonds de solidarité FTQ posts 8.9 pct return, $13.7 bln in assets

The Fonds de solidarité FTQ reported comprehensive income of $506 million in the first six months of its 2017-2018 financial year. The Montréal-based investor, led by President and CEO Gaétan Morin, also earned a 12-month return of 8.9 percent, which helped increase its net assets to $13.7 billion. During the six-month period ending November 30, Fonds de solidarité FTQ invested $526 million of development capital, primarily in Québec businesses, up from $287 million invested in the same period the year before.

Galen Partners targets $200 mln for sixth fund

Galen Partners is seeking to raise $200 million for its sixth fund, according to an SEC filing. Based in Stamford, Connecticut, the growth equity firm focuses on healthcare.

SunTx Capital nets over $94.7 mln for third fund

SunTx Capital Partners has raised over $94.7 million for its third fund, according to an SEC filing. No target was listed on the document. The Dallas-based private equity firm invests in middle-market manufacturing, distribution and service companies.

VC-backed Trieza Therapeutics appoints chief scientific officer

Cambridge, Massachusetts-based Trieza Therapeutics Inc, a biotech company focused on cancer immunotherapy, has named Dr. Jeno Gyuris as chief scientific officer. Gyuris is a former chief scientific officer at Aveo Pharmaceuticals. Trieza's backers include MPM Capital, Interwest Partners and Astellas Venture Management LLC.